FDA Warns Medline Over Defective Heart Syringes, Citing Patient Harm and Failed Fixes
Summary
The U.S. FDA has issued a warning letter to Medline Inc. regarding defective syringes used in heart procedures, specifically from its NAMIC division, following a December 2025 inspection. The letter, dated March 25, 2026, highlights Medline's failure to adequately address complaints dating back to June 2023, which led to 221 complaints and 177 safety reports, including incidents of air injection into a patient and biohazard exposure. The FDA also cited Medline for poor cleaning practices and inadequate safety testing, noting that the company's own risk assessment for potentially fatal air embolisms was inconsistent with its data. This is a highly material regulatory action for Medline, a significant medical device company, as it points to persistent product defects, failed remediation efforts, and systemic quality control issues. The recall of the syringes and the potential for product seizure, court action, or financial penalties could materially impact sales, profitability, and reputation. Investors should monitor Medline's response to the warning, the costs of remediation, and any potential legal or financial repercussions.
At the time of this announcement, MDLN was trading at $45.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $56.6B. The 52-week trading range was $38.00 to $50.88. This news item was assessed with negative market sentiment and an importance score of 9 out of 10. Source: Reuters.